Subfile:
Complementary and Alternative Medicine
Format (FM):
Fact Sheet (22). Speech/Statement (56).
Language(s) (LG):
English.
Year Published (YR):
2001.
Audience code (AC):
Researchers (117). Physicians (170). Patients (400).
Corporate Author (CN):
National Cancer Institute, National Institutes of Health.
Source (SO):
Bethesda, MD: National Cancer Institute. 2001. 7 p.
Availability (AV):
Available from National Cancer Institute. Publications Ordering Service, P.O. Box 24128, Baltimore, MD 21227. (800) 4-CANCER or (800) 422-6237; TTY: (800) 332-8615; FAX: (301) 330-7968.
PRICE: Free.
Abstract (AB):
This Physician Data Query (PDQ) statement provides information about a complementary and alternative medicine (CAM) treatment called Cancell/Entelev, which is used for cancer and a number of other diseases. It gives general information about Cancell/Entelev, including its chemical make-up, how the compound is administered, and its use as a CAM for cancer. The history of its discovery is traced and its possible mechanisms of action are described. The PDQ statement also provides details about results from a variety of studies of Cancell/Entelev, including laboratory, animal, preclinical, and human/clinical studies. The adverse effects of Cancell/Entelev are listed after the scientific evidence. The PDQ statement concludes with a ranking of the overall level of evidence for Cancell/Entelev. A glossary of terms is provided. 8 references.
Major Descriptors (MJ):
Cancel. Entelev. Research. Treatment. Cancer.
Minor Descriptors (MN):
National Cancer Institute. Chemical Constituents. Clinical Trials. Adverse Effects. Safety.
Verification/Update Date (VE):
200305.
Notes (NT):
Copyright: No.
Accession Number (AN):
AMDC03291.
URL (LK):
http://www.cancer.gov/cancer_information/doc.aspx?viewid=4C48A1A1- 2B8A-4EBD-B51D-3D196DA4F1CE
